243 related articles for article (PubMed ID: 25821099)
1. Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir.
Vo KP; Vutien P; Akiyama MJ; Vu VD; Ha NB; Piotrowski JI; Wantuck J; Roytman MM; Tsai N; Cheung R; Li J; Nguyen MH
Dig Dis Sci; 2015 Apr; 60(4):1045-51. PubMed ID: 25821099
[TBL] [Abstract][Full Text] [Related]
2. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
Cammà C; Petta S; Cabibbo G; Ruggeri M; Enea M; Bruno R; Capursi V; Gasbarrini A; Alberti A; Craxì A;
J Hepatol; 2013 Oct; 59(4):658-66. PubMed ID: 23707373
[TBL] [Abstract][Full Text] [Related]
4. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.
Faisal N; Yoshida EM; Bilodeau M; Wong P; Ma M; Burak KW; Al-Judaibi B; Renner EL; Lilly LB
Ann Hepatol; 2014; 13(5):525-32. PubMed ID: 25152985
[TBL] [Abstract][Full Text] [Related]
5. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.
Beste LA; Green PK; Ioannou GN
Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):123-9. PubMed ID: 25503739
[TBL] [Abstract][Full Text] [Related]
6. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
Miailhes P; Gilbert C; Lacombe K; Arends JE; Puoti M; Rockstroh JK; Sogni P; Fontaine H; Rosenthal E; Winnock M; Loko MA; Wittkop L; Dabis F; Salmon D;
Liver Int; 2015 Sep; 35(9):2090-9. PubMed ID: 25650873
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting.
Price JC; Murphy RC; Shvachko VA; Pauly MP; Manos MM
Dig Dis Sci; 2014 Dec; 59(12):3043-52. PubMed ID: 25102983
[TBL] [Abstract][Full Text] [Related]
8. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
Pungpapong S; Aqel BA; Koning L; Murphy JL; Henry TM; Ryland KL; Yataco ML; Satyanarayana R; Rosser BG; Vargas HE; Charlton MR; Keaveny AP
Liver Transpl; 2013 Jul; 19(7):690-700. PubMed ID: 23696372
[TBL] [Abstract][Full Text] [Related]
9. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.
Butt AA; Yan P; Shaikh OS; Freiberg MS; Lo Re V; Justice AC; Sherman KE;
J Viral Hepat; 2015 Sep; 22(9):691-700. PubMed ID: 25524834
[TBL] [Abstract][Full Text] [Related]
10. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
J Med Econ; 2014 Jan; 17(1):77-87. PubMed ID: 24032626
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
J Med Econ; 2014 Jan; 17(1):65-76. PubMed ID: 24160335
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
14. Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort.
Mauss S; Böker K; Buggisch P; Christensen S; Hofmann WP; Schott E; Pfeiffer-Vornkahl H; Alshuth U; Hüppe D
Z Gastroenterol; 2015 Jul; 53(7):644-54. PubMed ID: 26167694
[TBL] [Abstract][Full Text] [Related]
15. Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin.
Gordon SC; Yoshida EM; Lawitz EJ; Bacon BR; Sulkowski MS; Davis M; Poordad F; Bronowicki JP; Esteban R; Sniukiene V; Burroughs MH; Deng W; Dutko FJ; Brass CA; Albrecht JK; Rajender Reddy K
Aliment Pharmacol Ther; 2013 Jul; 38(1):16-27. PubMed ID: 23710734
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.
Salmerón J; Vinaixa C; Berenguer R; Pascasio JM; Sánchez Ruano JJ; Serra MÁ; Gila A; Diago M; Romero-Gómez M; Navarro JM; Testillano M; Fernández C; Espinosa D; Carmona I; Pons JA; Jorquera F; Rodriguez FJ; Pérez R; Montero JL; Granados R; Fernández M; Martín AB; Muñoz de Rueda P; Quiles R;
World J Gastroenterol; 2015 Aug; 21(30):9163-74. PubMed ID: 26290644
[TBL] [Abstract][Full Text] [Related]
17. Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
Wedemeyer H; Forns X; Hézode C; Lee SS; Scalori A; Voulgari A; Le Pogam S; Nájera I; Thommes JA
PLoS One; 2016; 11(1):e0145409. PubMed ID: 26752189
[TBL] [Abstract][Full Text] [Related]
18. Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir.
Benito JM; Sánchez-Parra C; Maida I; Aguilera A; Rallón NI; Rick F; Labarga P; Fernández-Montero JV; Barreiro P; Soriano V
Antivir Ther; 2013; 18(5):709-15. PubMed ID: 23645335
[TBL] [Abstract][Full Text] [Related]
19. Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.
Sterling RK; Kuo A; Rustgi VK; Sulkowski MS; Stewart TG; Fenkel JM; El-Genaidi H; Mah'moud MA; Abraham GM; Stewart PW; Akushevich L; Nelson DR; Fried MW; Di Bisceglie AM
Aliment Pharmacol Ther; 2015 Apr; 41(7):671-85. PubMed ID: 25627020
[TBL] [Abstract][Full Text] [Related]
20. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
